← Back to Search

Anti-tumor antibiotic

Aldoxorubicin for Small Cell Lung Cancer

Phase 2
Waitlist Available
Research Sponsored by CytRx
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 36 months
Awards & highlights

Study Summary

The purpose of this study is to evaluate the efficacy and safety of aldoxorubicin compared to topotecan in subjects with metastatic small cell lung cancer.

Eligible Conditions
  • Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~36 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression-Free Survival (PFS)
Secondary outcome measures
Overall Survival (OS)
Safety Measures

Side effects data

From 2019 Phase 2 trial • 35 Patients • NCT01931098
78%
Hypertension
67%
Fatigue
44%
Diarrhea
33%
Vomiting
33%
White blood cell decreased
33%
Cognitive disturbance
33%
Dysgeusia
33%
Seizure
33%
Nausea
22%
Weight loss
22%
Muscle weakness left-sided
22%
Anorexia
22%
Cough
22%
Gait disturbance
22%
Headache
22%
Neutrophil count decreased
22%
Pain
11%
Gastroesophageal reflux disease
11%
Musculoskeletal and connective tissue disorder - Other, specify
11%
Alanine aminotransferase increased
11%
Anemia
11%
Arthralgia
11%
Aspartate aminotransferase increased
11%
Bruising
11%
Depression
11%
Dizziness
11%
Dry mouth
11%
Dry skin
11%
Dysphagia
11%
Dysphasia
11%
Fall
11%
Flank pain
11%
Flu like symptoms
11%
Hematuria
11%
Hoarseness
11%
Hypernatremia
11%
Insomnia
11%
Lymphocyte count decreased
11%
Paresthesia
11%
Purpura
11%
Respiratory, thoracic and mediastinal disorders - Other, Congestion
11%
Sinus tachycardia
11%
Sinusitis
11%
Skin and subcutaneous tissue disorders - Other, Lacerations on legs
11%
Sore throat
11%
Spasticity
11%
Urinary urgency
11%
Oral pain
11%
Meningitis
11%
Eye disorders - Other, Left upper quadrant defect
11%
Gastrointestinal disorders - Other, specify
11%
Stroke
11%
Platelet count decreased
11%
Eye disorders - Other, Right Hemianops
11%
Hypoalbuminemia
11%
Hypocalcemia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure
Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: AldoxorubicinExperimental Treatment1 Intervention
Group II: TopotecanActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Aldoxorubicin
Not yet FDA approved

Find a Location

Who is running the clinical trial?

CytRxLead Sponsor
21 Previous Clinical Trials
1,435 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
2014. "Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02200757.
All > Sclc
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top